Medtronic’s Valiant stent graft shows efficacy in new trial

Medtronic has highlighted data from a new trial that demonstrates the high-quality clinical results provided by its Valiant thoracic stent graft system.

The medical device was recently utilised in a pivotal study called Valor II, in which it was trialled among 160 US patients requiring thoracic endovascular aortic repair of thoracic aortic aneurysms (TAA).

During the trial, the stent graft was able to meet all of its safety and efficacy endpoints, demonstrating a high rate of successful aneurysm treatments and a minimal rate of all-cause mortality.

It was noted that there were no cases of rupture or conversion to open surgery among the trial group, while very few stent grafts migrated from their original placement.

Lead investigator Dr Ronald Fairman of the University of Pennsylvania said: "The Valor II 12-month results demonstrate that the Medtronic Valiant stent graft is a safe and effective treatment for patients with descending TAA of degenerative etiology."

Last month, the firm showcased results from a study of its Resolute drug-eluting stent system, demonstrating the benefits it offers to heart disease and diabetes patients.